ZUERICH, SWITZERLAND / ACCESSWIRE / June 16, 2021 / curasan AG, a number one world supplier of biomaterials for bone and tissue regeneration in dental and orthopedic surgical procedure, and Xlife Sciences AG have initiated a collaboration within the discipline of regenerative medication. Beneath the settlement it’s meant to develop, produce, certify and market new merchandise with a give attention to the musculoskeletal space and tissue regeneration.
The primary emphasis of the collaboration lies on the biologization of bone substitute supplies and the event of an modern manufacturing course of. On this context, on the one hand, bone substitute merchandise are to be manufactured utilizing 3D printing processes by a mission firm of Xlife Sciences AG. The primary collection of exams have already yielded promising outcomes. Alternatively, service supplies are to be optimized for improved biofunctionality with substances that promote bone progress. For this function, new kinds of modalities, so-called exosomes, are launched into the bone substitute materials. Exosomes are bioactive nanoparticles which are secreted by stem cells or obtained from human platelets; these include, amongst different molecules, progress components and microRNAs.
“The cooperation with Xlife Sciences AG and its mission firms offers curasan entry to probably the most trendy manufacturing processes in addition to promising new therapies in musculoskeletal regeneration. Specifically, using exosomes along side the tried and examined curasan merchandise has monumental potential in tissue regeneration, “says Dirk Dembski, CEO of curasan AG. The Exosome Market recorded gross sales of roughly $ 174.04M in 2020 and is anticipated to expertise a CAGR (Common Annual Development Charge) of 27.89% over the forecast interval (2021-2026) *
*Supply: https://www.mordorintelligence.com/industry-reports/exosomes-market
About Xlife Sciences AG
Xlife Sciences AG is a Swiss firm with give attention to investing in promising applied sciences within the life science trade. Xlife Sciences AG is constructing the bridge from analysis and growth to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, creating and implementing their ideas. Along with industrial companions or universities, Xlife Sciences AG leads tasks by the proof-of-concept section after an invention disclosure or start-up. Subsequently, the agency focuses on out-licensing or promoting the corporate, typically with a mix of a strategic partnership. Xlife Sciences AG affords its traders direct entry to the additional growth of modern and future-oriented applied sciences at a really early stage.
For extra info, please go to: www.xlifesciences.ch
About curasan AG
curasan develops, produces and markets biomaterials and medical gadgets for bone and tissue regeneration.
As a world expertise chief within the future-oriented progress market of regenerative medication, our firm is specialised in biomimetic bone grafting supplies mimicking organic constructions for the use in orthopedics, traumatology, backbone surgical procedure and dental implantology.
Additional info: https://www.curasan.de/en/company/about-us/
For media inquiries:
Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Tel. +41 44 385 84 60, dennis.lennartz@xlifesciences.ch
Andrea Weidner, Company Communications, curasan AG, Tel. +49 6027 40 900 51, pr@curasan.com
For scientific inquiries:
Dr. Frank Plöger, Chief Scientific Officer, Xlife Sciences AG, Tel. +41 44 385 84 62, frank.ploeger@xlifesciences.ch
SOURCE: Xlife Sciences AG
View supply model on accesswire.com:
https://www.accesswire.com/651921/Xlife-Sciences-AG-curasan-AG-and-Xlife-Sciences-AG-Cooperate-in-the-Field-of-Regenerative-Medicine
